PREMPHASE (PREMARIN;CYCRIN 14/14)
LOE Approachingestrogens, conjugated; medroxyprogesterone acetate
NDAORAL-28TABLET
Approved
Dec 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PREMPHASE is an oral hormone replacement therapy (HRT) combining conjugated estrogens (PREMARIN) and medroxyprogesterone acetate (CYCRIN) in a 28-day cyclic regimen. It is indicated for relief of moderate-to-severe vasomotor symptoms (hot flashes, night sweats) and vulvar/vaginal atrophy associated with menopause. The estrogen component provides symptom relief while the progestin protects against endometrial hyperplasia.
LOE Approaching
Product is in advanced stages of patent life with LOE approaching; commercial teams are likely focused on lifecycle management, generic preparation, and market transition strategies rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PREMPHASE offers limited career growth given its LOE-approaching status and zero linked job openings; roles focus on managed decline, generic defense, and market transition rather than expansion. Professionals joining this product should expect smaller teams, defensive strategies, and potential reassignment as the franchise transitions post-LOE.
Brand ManagerField Sales Representative
Worked on PREMPHASE (PREMARIN;CYCRIN 14/14) at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.